First Alzheimer’s drug authorised in Switzerland
Keystone-SDA
The Swiss medicines regulator Swissmedic has for the first time authorised a drug (Donanemab) that can slow down the progression of Alzheimer’s disease.
+Get the most important news from Switzerland in your inbox
Swissmedic rates the benefits of the active substance higher than possible side effects. In a joint press release with Swiss Memory Clinics, Alzheimer Switzerland welcomed the authorisation.
+ Swiss regulators weigh hope and hype with new Alzheimer’s drugs
The antibody Donanemab, developed by Eli Lilly under the trade name Kisunla, reduces protein deposits in the brain. It is intended for patients in the early stages of the disease and is designed to delay cognitive decline.
However, the treatment also has potential risks such as brain swelling or bleeding and requires careful monitoring.
It is still unclear whether the costs will be covered by health insurance companies.
More
More
Science podcast: cracking the Alzheimer’s code
Adapted from German by AI/mga
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
